In vitro activity of MDL 62,879 against gram-positive bacteria and Bacteroides species.
The new thiazolyl peptide antibiotic MDL 62,879 (GE2270 A) showed excellent in vitro activity in testing against staphylococci and streptococci, with MIC90s ranging from 0.23 to 0.9 mg/l. It was very active against Clostridium difficile and Propionibacterium acnes (MIC90 0.06 mg/l in each case) and had variable activity against Bacteroides spp. MDL 62,879 had exceptionally good activity against Enterococcus faecalis, including against a collection of high-level aminoglycoside-resistant isolates where it had an MIC90 of 0.047. The antibiotic was bacteriostatic for enterococcal isolates but bactericidal for a methicillin-resistant isolate of Staphylococcus aureus.
Bartoloni
A
A
Clinica di Malattie Infettive, Università di Firenze, Italy.
Mantella
A
A
Goldstein
B P
BP
Denaro
M
M
Nicoletti
P
P
Paradisi
F
F
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001439:Bacteroides / Q000187:drug effects*; D002981:Clindamycin / Q000494:pharmacology; D006020:Glycopeptides; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D010406:Penicillins / Q000494:pharmacology*; D010456:Peptides, Cyclic; D013844:Thiazoles / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D010406:Penicillins; D010456:Peptides, Cyclic; D013844:Thiazoles; D002981:Clindamycin; C068122:GE 2270 A